Asia Pacific Active Pharmaceutical Ingredients (API) Market 2027

Bonafide Trust 26-02-2021 166 Pages Figures : 67 Tables : 97
Region : Asia-Pacific Category : Lifescience Pharmaceutical

Request new version

Request for updated version of the report at the same price

Order Now

Highend Report

Highend report of this product is available

View

Report Description
Table of Contents
List of Figure Tables

Download Page

Asia Pacific active pharmaceutical ingredients (API) market will grow by 9.0% annually with a total addressable market cap of $636.1 billion over 2021-2027 driven by the rising need for medicine and pharmaceutical agents amid the COVID-19 pandemic. Highlighted with 97 tables and 67 figures, this 166-page report “Asia Pacific Active Pharmaceutical Ingredients (API) Market 2021-2027 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific API market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2020 and provides forecast from 2021 till 2027 with 2020 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific API market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country. Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section. Synthetic API • Branded Synthetic API • Generic Synthetic API Biotech API by Drug Type: • Monoclonal Antibodies • Recombinant Proteins • Vaccines • Other Biotech APIs Biotech API by Customer Base: • Innovative Biologic API • Generic Biosimilar API Biotech API by Expression Technology: • Mammalian Expression • Microbial Expression • Yeast Expression • Insect Expression • Other Expression Technologies HPAPI • Branded HPAPI • Generic HPAPI Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section. Captive Manufacturing • Branded Captive API • Generic Captive API Merchant Manufacturing by Drug Type: • Branded Merchant API • Generic Merchant API Merchant Manufacturing by Drug Synthesis: • Merchant Synthetic API • Merchant Biotech API Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section. • Infectious Diseases • Oncology • Ophthalmology • Cardiovascular Disorders • Central Nervous System • Pulmonary Disorders • Orthopedics • Other Applications Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2017-2027 included in each section. • Branded Prescription Drugs • Generic Prescription Drugs • OTC Drugs Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue are available for 2017-2027. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in Asia Pacific API market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AbbVie Inc. Astrazeneca Aurobindo Pharma Ltd. BASF Bayer AG Boehringer Ingelheim Dr. Reddy's Laboratories F. Hoffmann-La Roche GlaxoSmithKline plc Lonza Group Lupin Limited Merck & Co., Inc. Mylan NV Novartis International AG Pfizer Inc. Sanofi Sun Pharmaceutical Industries Ltd. Teva Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 9

1.1 Industry Definition and Research Scope 9

1.1.1 Industry Definition 9

1.1.2 Research Scope 10

1.2 Research Methodology 13

1.2.1 Overview of Market Research Methodology 13

1.2.2 Market Assumption 14

1.2.3 Secondary Data 14

1.2.4 Primary Data 14

1.2.5 Data Filtration and Model Design 16

1.2.6 Market Size/Share Estimation 17

1.2.7 Research Limitations 18

1.3 Executive Summary 19

2 Market Overview and Dynamics 21

2.1 Market Size and Forecast 21

2.1.1 Impact of COVID-19 on World Economy 22

2.1.2 Impact of COVID-19 on the Market 25

2.2 Major Growth Drivers 27

2.3 Market Restraints and Challenges 32

2.4 Emerging Opportunities and Market Trends 35

2.5 Porter’s Fiver Forces Analysis 39

3 Segmentation of Asia Pacific Market by Synthesis 43

3.1 Market Overview by Synthesis 43

3.2 Synthetic API 45

3.2.1 Branded Synthetic API 46

3.2.2 Generic Synthetic API 47

3.3 Biotech API 48

3.3.1 Biotech API by Drug Type 49

3.3.1.1 Monoclonal Antibodies 50

3.3.1.2 Recombinant Proteins 51

3.3.1.3 Vaccines 52

3.3.1.4 Other Biotech APIs 53

3.3.2 Biotech API by Customer Base 54

3.3.2.1 Innovative Biologic API 55

3.3.2.2 Generic Biosimilar API 56

3.3.3 Biotech API by Expression Technology 57

3.3.3.1 Mammalian Expression 58

3.3.3.2 Microbial Expression 59

3.3.3.3 Yeast Expression 60

3.3.3.4 Insect Expression 61

3.3.3.5 Other Expression Technologies 62

3.4 HPAPI 63

3.4.1 Branded HPAPI 64

3.4.2 Generic HPAPI 65

4 Segmentation of Asia Pacific Market by Manufacturing Process 66

4.1 Market Overview by Manufacturing Process 66

4.2 Captive Manufacturing 68

4.2.1 Branded Captive API 69

4.2.2 Generic Captive API 70

4.3 Merchant Manufacturing 71

4.3.1 Merchant Manufacturing by Drug Type 72

4.3.1.1 Branded Merchant API 73

4.3.1.2 Generic Merchant API 74

4.3.2 Merchant Manufacturing by Drug Synthesis 75

4.3.2.1 Merchant Synthetic API 76

4.3.2.2 Merchant Biotech API 77

5 Segmentation of Asia Pacific Market by Therapeutic Application 78

5.1 Market Overview by Therapeutic Application 78

5.2 Infectious Diseases 80

5.3 Oncology 81

5.4 Ophthalmology 82

5.5 Cardiovascular Disorders 83

5.6 Central Nervous System 84

5.7 Pulmonary Disorders 85

5.8 Orthopedics 86

5.9 Other Applications 87

6 Segmentation of Asia Pacific Market by Drug Type 88

6.1 Market Overview by Drug Type 88

6.2 Branded Prescription Drugs 90

6.3 Generic Prescription Drugs 91

6.4 OTC Drugs 92

7 Asia-Pacific Market 2020-2027 by Country 93

7.1 Overview of Asia-Pacific Market 93

7.2 China 96

7.3 Japan 98

7.4 India 101

7.5 Australia 103

7.6 South Korea 105

7.7 Rest of APAC Region 107

8 Competitive Landscape 109

8.1 Overview of Key Vendors 109

8.2 New Product Launch, Partnership, Investment, and M&A 112

8.3 Company Profiles 113

AbbVie Inc. 113

Astrazeneca 115

Aurobindo Pharma Ltd. 118

BASF 120

Bayer AG 123

Boehringer Ingelheim 125

Dr. Reddy's Laboratories 129

F. Hoffmann-La Roche 131

GlaxoSmithKline plc 133

Lonza Group 137

Lupin Limited 141

Merck & Co., Inc. 143

Mylan NV 145

Novartis International AG 147

Pfizer Inc. 149

Sanofi 153

Sun Pharmaceutical Industries Ltd. 155

Teva Pharmaceutical Industries Ltd. 157

9 Investing in Asia Pacific Market: Risk Assessment and Management 160

9.1 Risk Evaluation of Asia Pacific Market 160

9.2 Critical Success Factors (CSFs) 163

Related Reports and Products 166

Figure 1. Research Method Flow Chart 13
Figure 2. Breakdown of Primary Research 15
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 17
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 19
Figure 5. Asia Pacific Active Pharmaceutical Ingredients (API) Market, 2020-2027, $ bn 21
Figure 6. Impact of COVID-19 on Business 25
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Active Pharmaceutical Ingredients (API) Market 27
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 30
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 30
Figure 10. Primary Restraints and Impact Factors of Asia Pacific Active Pharmaceutical Ingredients (API) Market 32
Figure 11. Investment Opportunity Analysis 36
Figure 12. Porter’s Fiver Forces Analysis of Asia Pacific Active Pharmaceutical Ingredients (API) Market 39
Figure 13. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis, 2020-2027, % of Revenue 43
Figure 14. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Synthesis, Value ($ bn) and Share (%) 44
Figure 15. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Synthetic API, 2017-2027, $ bn 45
Figure 16. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Branded Synthetic API, 2017-2027, $ bn 46
Figure 17. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Generic Synthetic API, 2017-2027, $ bn 47
Figure 18. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API, 2017-2027, $ bn 48
Figure 19. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Monoclonal Antibodies, 2017-2027, $ bn 50
Figure 20. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Recombinant Proteins, 2017-2027, $ bn 51
Figure 21. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Vaccines, 2017-2027, $ bn 52
Figure 22. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Other Biotech APIs, 2017-2027, $ bn 53
Figure 23. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Innovative Biologic API, 2017-2027, $ bn 55
Figure 24. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Generic Biosimilar API, 2017-2027, $ bn 56
Figure 25. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Mammalian Expression, 2017-2027, $ bn 58
Figure 26. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Microbial Expression, 2017-2027, $ bn 59
Figure 27. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Yeast Expression, 2017-2027, $ bn 60
Figure 28. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Insect Expression, 2017-2027, $ bn 61
Figure 29. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Other Expression Technologies, 2017-2027, $ bn 62
Figure 30. Asia Pacific Active Pharmaceutical Ingredients (API) Market: HPAPI, 2017-2027, $ bn 63
Figure 31. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Branded HPAPI, 2017-2027, $ bn 64
Figure 32. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Generic HPAPI, 2017-2027, $ bn 65
Figure 33. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2020-2027, % of Revenue 66
Figure 34. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Manufacturing Process, Value ($ bn) and Share (%) 67
Figure 35. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing, 2017-2027, $ bn 68
Figure 36. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Branded Captive API, 2017-2027, $ bn 69
Figure 37. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Generic Captive API, 2017-2027, $ bn 70
Figure 38. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing, 2017-2027, $ bn 71
Figure 39. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Branded Merchant API, 2017-2027, $ bn 73
Figure 40. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Generic Merchant API, 2017-2027, $ bn 74
Figure 41. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Synthetic API, 2017-2027, $ bn 76
Figure 42. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Biotech API, 2017-2027, $ bn 77
Figure 43. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2020-2027, % of Revenue 78
Figure 44. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%) 79
Figure 45. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Infectious Diseases, 2017-2027, $ bn 80
Figure 46. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Oncology, 2017-2027, $ bn 81
Figure 47. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Ophthalmology , 2017-2027, $ bn 82
Figure 48. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Cardiovascular Disorders, 2017-2027, $ bn 83
Figure 49. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Central Nervous System, 2017-2027, $ bn 84
Figure 50. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Pulmonary Disorders, 2017-2027, $ bn 85
Figure 51. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Orthopedics, 2017-2027, $ bn 86
Figure 52. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Other Applications, 2017-2027, $ bn 87
Figure 53. Breakdown of Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type, 2020-2027, % of Revenue 88
Figure 54. Contribution to Asia Pacific 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%) 89
Figure 55. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Branded Prescription Drugs, 2017-2027, $ bn 90
Figure 56. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Generic Prescription Drugs, 2017-2027, $ bn 91
Figure 57. Asia Pacific Active Pharmaceutical Ingredients (API) Market: OTC Drugs, 2017-2027, $ bn 92
Figure 58. Breakdown of APAC Active Pharmaceutical Ingredients (API) Market by Country, 2020 and 2027, % of Revenue 94
Figure 59. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%) 95
Figure 60. Active Pharmaceutical Ingredients (API) Market in China, 2017-2027, $ bn 96
Figure 61. Active Pharmaceutical Ingredients (API) Market in Japan, 2017-2027, $ bn 99
Figure 62. Active Pharmaceutical Ingredients (API) Market in India, 2017-2027, $ bn 101
Figure 63. Active Pharmaceutical Ingredients (API) Market in Australia, 2017-2027, $ bn 103
Figure 64. Active Pharmaceutical Ingredients (API) Market in South Korea, 2017-2027, $ bn 105
Figure 65. Active Pharmaceutical Ingredients (API) Market in Rest of APAC, 2017-2027, $ bn 107
Figure 66. Growth Stage of Asia Pacific Active Pharmaceutical Ingredients (API) Industry over the Forecast Period 109
Figure 67. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars) 116

Table 1. Snapshot of Asia Pacific Active Pharmaceutical Ingredients (API) Market in Balanced Perspective, 2020-2027 20
Table 2. Growth Rate of World Real GDP, 2017-2021 23
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 31
Table 4. Main Product Trends and Market Opportunities in Asia Pacific Active Pharmaceutical Ingredients (API) Market 35
Table 5. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 43
Table 6. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Synthetic API by Drug Type, 2017-2027, $ bn 45
Table 7. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Drug Type, 2017-2027, $ bn 49
Table 8. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Customer Base, 2017-2027, $ bn 54
Table 9. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Biotech API by Expression Technology, 2017-2027, $ bn 57
Table 10. Asia Pacific Active Pharmaceutical Ingredients (API) Market: HPAPI by Drug Type, 2017-2027, $ bn 63
Table 11. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 66
Table 12. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Captive Manufacturing by Drug Type, 2017-2027, $ bn 68
Table 13. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Type, 2017-2027, $ bn 72
Table 14. Asia Pacific Active Pharmaceutical Ingredients (API) Market: Merchant Manufacturing by Drug Synthesis, 2017-2027, $ bn 75
Table 15. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 78
Table 16. Asia Pacific Active Pharmaceutical Ingredients (API) Market by Drug Type, 2017-2027, $ bn 88
Table 17. APAC Active Pharmaceutical Ingredients (API) Market by Country, 2017-2027, $ bn 94
Table 18. China Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 97
Table 19. China Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 97
Table 20. China Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 97
Table 21. Japan Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 100
Table 22. Japan Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 100
Table 23. Japan Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 100
Table 24. India Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 102
Table 25. India Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 102
Table 26. India Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 102
Table 27. Australia Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 104
Table 28. Australia Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 104
Table 29. Australia Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 104
Table 30. South Korea Active Pharmaceutical Ingredients (API) Market by Synthesis, 2017-2027, $ bn 106
Table 31. South Korea Active Pharmaceutical Ingredients (API) Market by Manufacturing Process, 2017-2027, $ bn 106
Table 32. South Korea Active Pharmaceutical Ingredients (API) Market by Therapeutic Application, 2017-2027, $ bn 106
Table 33. Active Pharmaceutical Ingredients (API) Market in Rest of APAC by Country, 2017-2027, $ bn 108
Table 34. AbbVie Inc.: Company Snapshot 113
Table 35. AbbVie Inc.: Product Portfolio 113
Table 36. AbbVie Inc.: Revenue, 2017-2019, $ bn 114
Table 37. Astrazeneca: Company Snapshot 115
Table 38. Astrazeneca: Revenue, 2017-2019, $ bn 116
Table 39. Aurobindo Pharma Ltd.: Company Snapshot 118
Table 40. Aurobindo Pharma Ltd.: Product Portfolio 119
Table 41. Aurobindo Pharma Ltd.: Revenue, 2016-2020, $ INR million 119
Table 42. BASF: Company Snapshot 120
Table 43. BASF: Business Segmentation 121
Table 44. BASF: Revenue, 2016-2018, Euro million 121
Table 45. Bayer AG: Company Snapshot 123
Table 46. Bayer AG: Business Segmentation 124
Table 47. Bayer AG: Revenue, 2016-2018, € bn 124
Table 48. Bayer AG: Recent Developments 124
Table 49. Boehringer Ingelheim: Company Snapshot 125
Table 50. Boehringer Ingelheim: Business Segmentation in 2019 126
Table 51. Boehringer Ingelheim: Product Portfolio 126
Table 52. Boehringer Ingelheim: Revenue, 2017-2019, EUR million 127
Table 53. Boehringer Ingelheim: Revenue by Region in 2019 127
Table 54. Boehringer Ingelheim: Recent Developments 127
Table 55. Dr. Reddy's Laboratories: Company Snapshot 129
Table 56. Dr. Reddy's Laboratories: Business Segmentation 129
Table 57. Dr. Reddy's Laboratories: Revenue, 2018-2020, $ bn 130
Table 58. F. Hoffmann-La Roche: Company Snapshot 131
Table 59. AbbVie Inc.: Business Segmentation 131
Table 60. F. Hoffmann-La Roche: Revenue, 2017-2019, $ bn 132
Table 61. GlaxoSmithKline: Company Snapshot 133
Table 62. GlaxoSmithKline: Business Segmentation 134
Table 63. GlaxoSmithKline: Product Portfolio 135
Table 64. GlaxoSmithKline: Revenue, 2016-2018, $ bn 136
Table 65. GlaxoSmithKline: Recent Developments 136
Table 66. Lonza Group: Company Snapshot 137
Table 67. Lonza Group: Business Segmentation in 2018 138
Table 68. Lonza Group: Product Portfolio 138
Table 69. Lonza Group: Revenue, 2017-2019, $ billion 139
Table 70. Lonza Group: Revenue by Region in 2018 139
Table 71. Lonza Group: Recent Developments 140
Table 72. Lupin Limited: Company Snapshot 141
Table 73. Lupin Limited: Business Segmentation 141
Table 74. Lupin Limited: Revenue, 2016-2018, INR billion 142
Table 75. Merck & Co., Inc.: Company Snapshot 143
Table 76. Merck & Co., Inc.: Business Segmentation 143
Table 77. Merck & Co., Inc.: Revenue, 2017-2019, $ bn 144
Table 78. Mylan NV: Company Snapshot 145
Table 79. Mylan NV: Revenue, 2017-2019, $ bn 146
Table 80. Novartis International AG: Company Snapshot 147
Table 81. Novartis International AG: Business Segmentation 147
Table 82. Novartis International AG: Revenue, 2017-2019, $ bn 148
Table 83. Pfizer Inc.: Company Snapshot 149
Table 84. Pfizer Inc.: Business Segmentation 150
Table 85. Pfizer Inc.: Product Portfolio 150
Table 86. Pfizer Inc.: Revenue, 2016-2018, $ bn 151
Table 87. Pfizer Inc.: Recent Developments 151
Table 88. Sanofi: Company Snapshot 153
Table 89. Sanofi: Business Segmentation 153
Table 90. Sanofi: Revenue, 2017-2019, $ bn 154
Table 91. Sun Pharmaceutical Industries Limited: Company Snapshot 155
Table 92. Sun Pharmaceutical Industries Limited: Revenue, 2017-2019, INR bn 156
Table 93. Teva Pharmaceutical Industries Ltd.: Company Snapshot 157
Table 94. Teva Pharmaceutical Industries Ltd.: Business Segmentation 158
Table 95. Teva Pharmaceutical Industries Ltd.: Revenue, 2017-2019, $ bn 158
Table 96. Risk Evaluation for Investing in Asia Pacific Market, 2020-2027 161
Table 97. Critical Success Factors and Key Takeaways 164

Interested in this report?
Get your FREE sample!

Safe and Secure SSl Encryption

Licensing options

2480
USD

Single User License
Site License
Global User License

Client Rating

Requirement Gathering & Methodology

Data Collection Techniques

Our Research Team & Data Sourcing

Data Science & Analytical Tools

Data Visualization & Presentation Skills

Project/ Report Delivery & After Sales Services

Testimonial

READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.

PRODUCT DEVELOPMENT MANAGER

CEO

Vivek Arora

BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!

EXECUTIVE DIRECTOR

Rahul Roy

THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.

SALES DIRECTOR

Arjun Prasad

THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH

MARKETING MANAGER

President

Manish Verma

Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

MARKETING DIRECTOR

Gautam Saxena

The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.

PRODUCT MANAGER

Tom Stone

I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.

Associate Director

Mark Wood

Asia Pacific Active Pharmaceutical Ingredients (API) Market 2027

Asia Pacific Active Pharmaceutical Ingredients (API) Market 2027